Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer; JAB-8263, a BET inhibitor that is in a Phase IIa trial for solid tumors and hematologic malignancies; JAB-BX102, a humanized monoclonal antibody against CD73, which is in a Phase I/IIa trial; JAB-2485, a highly selective Aurora Kinase A (AURKA) inhibitor that is in a Phase I/IIa trial for solid tumors; JAB-23E73, an oral small-molecule pan-KRAS inhibitor that is in a Phase I trial for KRAS-mutant PDAC, CRC, NSCLC, and solid tumors; and JAB-30355, a bioavailable small molecule p53 reactivator that is in a Phase I trial for the treatment of patients with locally advanced or metastatic solid tumors. It is also developing IND-enabling candidates, including JAB-BX467, JAB-BX600, and JAB-BX700 for solid tumor indications. The company has a collaboration agreement with AstraZeneca AB to develop and commercialize JAB-23E73. Jacobio Pharmaceuticals Group Co., Ltd. was founded in 2015 and is headquartered in Beijing, China. Address: Building 8, Beijing, China